The study aimed to assess the in vitro efficacy of commercial available probiotics, using S. salivarius K12, such as Bactoblis®. These products are strategically positioned for the prevention of respiratory infections, and a total of 7 commercial probiotics were subjected to testing. The study results confirms that Bactoblis®is the superior probiotic formula, ensuring strong strain stabilibity and clinical efficacy.
Bactoblis®: Where Innovation Meets Excellence!
Bactoblis® innovation lies in a superior probiotic lozenge, ensuring strain stability and clinical efficacy. Unlike others, Bactoblis® consistently delivers the clinical efficacious dosage of 1 billion CFU throughout its whole shelf life, setting a global standard for other oral probiotics products. Bactoblis®is part of a new era with Medical Probiotics, where effectiveness is not just a goal but a reality.
Bactoblis® : The Genuine K12 Formula for Respiratory Infections
- Unbeatable: Bactoblis®stands out from other oral probiotics for its exceptional pathogen inhibition. It’s unique formula gives full protection to the oral cavity and throat.
- Unmatched: Bactoblis®delivers incredible results with a proven track record in 35 clinical trials and various success stories from satisfied patients.
- Unsurpassed: Bactoblis®ability to keep a healthy oral microbiota sets it apart from the rest. Made to be matched to patient’s needs!
Results
- Bactoblis® mantains the clinical efficacious dosage of 1 billion CFU throughout its entire shelf life.
- Bactoblis®demonstrates the strongest inhibition against the most common respiratory pathogens throughout its entire shelf life.
- Bactoblis®is the most stable formula at 24 month shelf life with the lowest water activity increase, a key element to mantain strain stability and efficacy.
- Bactoblis®ensures a superior probiotic strain stability within the formula through its packaging, especially designed to minimize oxygen and moisture vapor permeability.
Conclusion
- Bactoblis® distinguishes itself as the only clinically proven K12 formula, consistently demonstrating outstanding benefits across multiple studies aimed at addressing respiratory infections in children and teenagers.
- Bactoblis® not only boasts an exceptional track record of 35 clinical trials by setting the benchmark of oral probiotics, as well as demonstrating a remarkable ability to significantly decrease bacterial and viral infections rates by up to 90% compared to control groups.
- Bactoblis® differentiates by consistently providing the clinical efficacious dosage (1 Billion CFU) throughout its entire shelf life.
- Bactoblis® leads the way with the highest quality standards for oral probiotics, emphasizing rigorous protocols for consistent efficacy. This commitment encompasses various crucial aspects, including in-vitro efficacy and water activity.